Evidence map›Paper›PMID 35514434›Full record

ArticleMaterials today. Bio2022

Collecting and deactivating TGF-β1 hydrogel for anti-scarring therapy in post-glaucoma filtration surgery.

Ruiqi Wang, Boyang Chen, Haiying Wei, Wei Yan, Yuping Wu, Cao Wang, Bosong Zhang, Fengzhen Liu, Hui Tian, Xiongbiao Chen and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Silicosis: from pathogenesis to therapeutics.Frontiers in pharmacology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Ruiqi WangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, Heilongjiang Province, People's Republic of China.
Boyang ChenSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, Heilongjiang Province, People's Republic of China.
Haiying WeiThe First Affiliated Hospital, Harbin Medical University, 23 Youzheng Street, Harbin, 150001, Heilongjiang Province, PR China.
Wei YanThe First Affiliated Hospital, Harbin Medical University, 23 Youzheng Street, Harbin, 150001, Heilongjiang Province, PR China.
Yuping WuChiping People's Hospital, Liaocheng, 252100, PR China.
Cao WangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, Heilongjiang Province, People's Republic of China.
Bosong ZhangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, Heilongjiang Province, People's Republic of China.
Fengzhen LiuLiaocheng People's Hospital, Medical College of Liaocheng University, Liaocheng, 252000, PR China.
Hui TianSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, Heilongjiang Province, People's Republic of China.
Xiongbiao ChenDepartment of Mechanical Engineering, University of Saskatchewan, SK, S7N5A9, Canada.
Weiming TianSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, Heilongjiang Province, People's Republic of China.
Harbin Institute of Technology · CNHarbin Medical University · CNLiaocheng People's Hospital · CNLiaocheng University · CNUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scar formation can lead to glaucoma filtration surgery (GFS) failure, wherein transforming growth factor (TGF)-β is the core regulator. To reducing scar formation, this paper presents our study on the design of hydrogels to deactivate TGF-β1. We hypothesized that excess TGF-β1 can be removed from aqueous humor through the addition of oxidized hyaluronic acid (O-HA) hydrogels that are seeded with decorin (O-HA ​+ ​D). Immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) were performed to demonstrate the adsorption properties of O-HA ​+ ​D hydrogel, thus reducing the TGF-β1 concentration in aqueous humor. In the light that collagen contraction in human Tenon's capsule fibroblasts (HTFs) and the angiogenesis of human umbilical vein endothelial cells (HUVECs) can be activated by TGF-β1 and β2, we performed the quantitative analysis of polymerase chain reaction to determine the effect of O-HA ​+ ​D on the type I collagen, fibronectin, and angiogenesis. Our results illustrate that O-HA ​+ ​D can inhibit the increase of α-SMA expression in HTF induced by TGF-β1 and that O-HA ​+ ​D can inhibit the production of collagen I and fibronectin in HTF treated with TGF-β1. Furthermore, we performed in vivo studies by employing a rabbit model, where rabbits were treated with hydrogels post GFS. Our results demonstrate that, as compared with other groups, the rabbits treated with O-HA ​+ ​D had the greatest reduction in inflammatory cells with reduced level of collagen in wounds. Taken together, the present study paves the way toward the treatment of post-glaucoma fibrosis following surgery.

Indexed as

anti-scarring therapyDecorinGlaucoma filtration surgeryHydrogelTGF-β1

Identifiers

PMID35514434
PMCPMC9061788
OpenAlexW4224289969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.